Hydration Pharmaceuticals Company Ltd

Consumer Defensive AU HPC

0.013AUD
-(-%)

Last update at 2024-05-13T00:00:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.010.07
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -10.60717M -8.96650M -0.74366M -3.43415M -9.60229M
Minority interest - - - - -
Net income -10.60717M -8.96650M -0.74366M -3.43415M -9.60229M
Selling general administrative 6.17M 4.49M 4.61M 4.76M 9.10M
Selling and marketing expenses 9.23M 4.83M - - -
Gross profit 4.70M 2.58M 1.34M 1.38M -0.07526M
Reconciled depreciation - 0.00460M - - -
Ebit -10.70178M -5.32660M -3.29979M -3.40049M -
Ebitda -10.51596M -5.32326M - - -
Depreciation and amortization - 0.00334M - - -
Non operating income net other - - - - -
Operating income -10.51596M -5.32660M -0.74366M -3.43415M -9.60229M
Other operating expenses 19.80M 12.66M - - -
Interest expense 0.09M 3.64M 0.26M 0.03M 0.35M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00001M 0.00013M - - -
Net interest income -0.09120M -3.95351M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 5.05M - - -
Total revenue 9.10M 5.92M 3.76M 2.96M 4.16M
Total operating expenses 15.40M 9.32M - - -
Cost of revenue 4.40M 3.34M 2.42M 1.59M 4.24M
Total other income expense net 0.19M 1.41M - - -
Discontinued operations - - - - -
Net income from continuing ops -10.60717M -12.34864M - - -
Net income applicable to common shares -10.60717M -8.95166M -0.74366M -3.43415M -9.60229M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6.69M 10.39M 15.31M 4.45M 4.20M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.71M 1.01M 1.80M - -
Total liab 7.05M 6.41M 2.08M 2.44M 1.81M
Total stockholder equity -0.35825M 3.98M 13.23M 2.00M 2.39M
Deferred long term liab - - - - -
Other current liab 2.07M 2.22M 1.49M 0.09M -
Common stock 39.33M 36.61M 36.45M 16.49M 16.49M
Capital stock - 36.61M 50.22M - -
Retained earnings -43.07816M -34.97578M -24.38346M -15.41696M -14.67329M
Other liab - 0.02M 0.02M 0.02M 0.06M
Good will - - - - -
Other assets - 0.00000M - - -
Cash 1.84M 4.69M 10.67M 1.64M 2.74M
Cash and equivalents - - - - -
Total current liabilities 3.13M 2.68M 2.06M 2.42M 1.76M
Current deferred revenue - - - - -
Net debt 2.05M -0.97641M -10.67253M - -
Short term debt - 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total 3.89M 3.71M - - -
Other stockholder equity 0.00000M 2.34M -0.04825M 0.92M 0.56M
Property plant equipment - - 0.00000M 0.00334M 0.00875M
Total current assets 6.69M 10.39M 15.31M 4.44M 4.19M
Long term investments - - - - -
Net tangible assets - 3.98M 13.23M 2.00M 2.39M
Short term investments - - - - -
Net receivables 1.74M 1.31M 1.04M 0.79M 0.60M
Long term debt - 3.71M - - -
Inventory 2.39M 3.39M 1.79M 1.59M 0.78M
Accounts payable 1.06M 0.45M 0.57M 1.18M 0.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.39M 2.34M 1.21M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - 0.00000M 0.00000M - -
Capital lease obligations - - - - -
Long term debt total - 3.71M 0.00000M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - -
Change to liabilities 0.00000M -0.13263M 0.67M 0.18M -
Total cashflows from investing activities - 0.00000M 2.73M -0.02048M 0.00000M
Net borrowings 4.08M 4.08M 4.08M 4.08M -
Total cash from financing activities 4.08M 17.03M 17.03M 3.04M 0.00000M
Change to operating activities 0.67M -1.40286M -0.38096M 0.06M -
Net income -10.60717M -12.34864M -0.74366M -3.43415M -
Change in cash -5.98434M 9.03M -1.09147M 0.20M -5.43008M
Begin period cash flow 10.67M 1.64M - - -
End period cash flow 4.69M 10.67M 2.27M - -
Total cash from operating activities -9.75184M -8.07805M -3.86232M -2.78130M -5.39537M
Issuance of capital stock - 16.60M - - -
Depreciation - 0.00334M 0.02M 0.01M -
Other cashflows from investing activities - 0.00000M 2.75M - -
Dividends paid - - - - -
Change to inventory -1.72145M -0.20924M -0.71670M 0.72M -
Change to account receivables - -0.23795M -0.19197M -0.08196M -
Sale purchase of stock - 12.03M 0.00000M 3.04M 0.00000M
Other cashflows from financing activities - 4.99M -1.42124M -1.42124M -
Change to netincome 0.86M 2.53M -2.52146M -0.23438M -
Capital expenditures 0.00000M 0.00000M 0.02M 0.02M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - -8.07805M -3.86232M -2.78130M -5.39537M
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow -9.75184M -11.14351M - - -

Fundamentals

  • Previous Close 0.01
  • Market Cap3.98M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.69844M
  • Revenue TTM10.04M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM 4.70M
  • Diluted EPS TTM-0.06

Peer Comparison

Sector: Consumer Defensive Industry: Food Distribution

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HPC
Hydration Pharmaceuticals Company Ltd
- -% 0.01 - - 0.34 1.87 0.66 -0.8849
MTS
Metcash Ltd
-0.01 0.26% 3.84 13.82 15.29 0.27 3.75 0.35 9.09

Reports Covered

Stock Research & News

Profile

The Hydration Pharmaceuticals Company Limited markets and sells a range of liquid, tablet, and powder healthy hydration products in Australia, the Unites States, and Canada. It sells its products under the Hydralyte brand name through retail stores and e-commerce channels. The Hydration Pharmaceuticals Company Limited was founded in 2001 and is headquartered in San Diego, California.

Hydration Pharmaceuticals Company Ltd

9255 Towne Center Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Oliver Baker Chief Exec. Officer NA
Mr. Chris Kavanaugh Chief Financial Officer NA
Ms. Carlie Hodges Company Sec. NA
Mr. Oliver Baker Chief Executive Officer NA
Ms. Victoria Nadalin Company Secretary NA
Mr. Oliver Baker Chief Executive Officer NA
Ms. Victoria Nadalin Company Secretary NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).